Evaluating the therapeutic impact of tirzepatide in people with partial lipodystrophy - PubMed

5 hours ago

Tirzepatide was evaluated for its therapeutic impact in patients with partial lipodystrophy (PLD), a rare condition characterized by adipocyte absence/dysfunction leading to severe insulin resistance.
The study was a single-center, retrospective, observational analysis involving 40 PLD patients, predominantly female (87.5%), with a median age of 47 and BMI of 31.5 kg/m².
After a median follow-up of 9.5 months, significant reductions were observed in body weight (91.0kg to 82.8kg), HbA1c (65 to 52 mmol/mol), serum triglycerides (2.80 to 1.83 mmol/L), and daily insulin requirements (177.5 to 58.0 IU).
The findings suggest tirzepatide's effectiveness in improving metabolic parameters in PLD patients, with recommendations for further prospective studies to validate these results and assess early intervention impacts.

Hasty Briefsbeta